Orchid Pharma Limited has informed the Exchange about Investor Presentation
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma filed its Q1 FY26 investor presentation showing sales of Rs 173 Cr, down 29% from Rs 244 Cr in Q1 FY25. However, the full FY25 picture remained healthy with annual sales of Rs 922 Cr, up 13% from Rs 819 Cr in FY24. Q1 profitability took a hit — EBITDA fell 27% to Rs 30 Cr and PAT dropped 38% to Rs 18 Cr. The silver lining is that EBITDA margin held steady at 17% and gross margin actually improved to 43% from 39% a year ago, suggesting the topline dip is not a margin story. The 5-year trend (Q1-22 to Q1-26) shows clear structural improvement, with EBITDA margins rising from 8% to 17% and the company turning from loss-making to consistently profitable.
The sharp sequential-quarter YoY sales decline in Q1 may worry investors, but steady margins, gross margin expansion, and the strong FY25 print suggest the business is fundamentally healthy with a possible base-effect or one-off drag. Watch for management commentary in the earnings call for clarity on the Q1 softness.